Henry H. Armstrong Associates’s Johnson & Johnson JNJ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$82M Buy
322,853
+2,757
+0.9% +$643K 7.94% 4
2026
Q1
$78.2M Sell
320,096
-701
-0.2% -$163K 7.97% 4
2025
Q4
$66.4M Sell
320,797
-7,014
-2% -$1.39M 6.17% 5
2025
Q3
$60.8M Sell
327,811
-2,668
-0.8% -$457K 5.5% 5
2025
Q2
$50.5M Sell
330,479
-15,633
-5% -$2.4M 4.76% 6
2025
Q1
$57.4M Sell
346,112
-4,544
-1% -$711K 5.56% 6
2024
Q4
$50.7M Sell
350,656
-9,367
-3% -$1.45M 5.07% 6
2024
Q3
$58.3M Sell
360,023
-6,527
-2% -$1.04M 5.59% 6
2024
Q2
$53.6M Sell
366,550
-9,239
-2% -$1.37M 5.35% 6
2024
Q1
$59.4M Sell
375,789
-4,514
-1% -$718K 5.78% 6
2023
Q4
$59.6M Sell
380,303
-9,950
-3% -$1.53M 6.33% 5
2023
Q3
$60.8M Sell
390,253
-3,025
-0.8% -$499K 6.94% 4
2023
Q2
$65.1M Sell
393,278
-7,208
-2% -$1.16M 7.19% 4
2023
Q1
$62.1M Sell
400,486
-13,237
-3% -$2.14M 7.56% 4
2022
Q4
$73.1M Sell
413,723
-5,115
-1% -$883K 9.06% 4
2022
Q3
$68.4M Buy
418,838
+2,368
+0.6% +$401K 9.27% 4
2022
Q2
$73.9M Buy
416,470
+3,085
+0.7% +$550K 9.33% 4
2022
Q1
$73.3M Sell
413,385
-5,573
-1% -$948K 7.73% 4
2021
Q4
$71.7M Sell
418,958
-4,759
-1% -$779K 7.52% 4
2021
Q3
$68.4M Sell
423,717
-1,194
-0.3% -$204K 7.92% 4
2021
Q2
$70M Buy
424,911
+608
+0.1% +$101K 8.04% 4
2021
Q1
$69.7M Sell
424,303
-1,224
-0.3% -$198K 8.59% 4
2020
Q4
$67M Sell
425,527
-4,415
-1% -$652K 8.82% 4
2020
Q3
$64M Sell
429,942
-3,333
-0.8% -$493K 8.87% 4
2020
Q2
$60.9M Sell
433,275
-1,029
-0.2% -$150K 9.13% 4
2020
Q1
$60M Buy
434,304
+3,991
+0.9% +$566K 9.94% 4
2019
Q4
$62.8M Sell
430,313
-1,774
-0.4% -$241K 9.04% 4
2019
Q3
$55.9M Sell
432,087
-2,380
-0.5% -$314K 9.17% 4
2019
Q2
$60.5K Sell
434,467
-49,514
-10% -$6.85M 8.27% 5
2019
Q1
$67.7M Sell
483,981
-8,244
-2% -$1.1M 10.44% 4
2018
Q4
$63.5M Sell
492,225
-4,647
-0.9% -$648K 10.43% 4
2018
Q3
$68.7M Sell
496,872
-6,790
-1% -$902K 10.54% 4
2018
Q2
$61.1M Sell
503,662
-480
-0.1% -$59.9K 10.42% 4
2018
Q1
$65.8M Buy
504,142
+2,750
+0.5% +$372K 10.91% 4
2017
Q4
$70.1M Buy
501,392
+2,065
+0.4% +$288K 11.8% 3
2017
Q3
$64.9M Buy
499,327
+1,935
+0.4% +$257K 11.68% 3
2017
Q2
$65.8M Buy
497,392
+4,306
+0.9% +$549K 12.56% 3
2017
Q1
$61.4M Buy
493,086
+10
+0% +$1.2K 11.63% 3
2016
Q4
$56.8M Buy
493,076
+1,551
+0.3% +$179K 11.79% 3
2016
Q3
$58.1M Sell
491,525
-2,270
-0.5% -$275K 11.16% 3
2016
Q2
$59.9M Sell
493,795
-1,279
-0.3% -$145K 12.02% 2
2016
Q1
$53.6M Buy
495,074
+6,465
+1% +$669K 11.06% 3
2015
Q4
$50.2M Buy
488,609
+5,222
+1% +$525K 9.82% 3
2015
Q3
$45.1M Buy
483,387
+38,992
+9% +$3.77M 9.24% 3
2015
Q2
$43.3M Buy
444,395
+1,714
+0.4% +$172K 10.48% 2
2015
Q1
$44.5M Buy
442,681
+7,478
+2% +$760K 9.83% 2
2014
Q4
$45.5M Buy
435,203
+2,049
+0.5% +$216K 9.85% 2
2014
Q3
$46.2M Buy
433,154
+11,844
+3% +$1.23M 10.57% 2
2014
Q2
$44.1M Buy
421,310
+854
+0.2% +$86.3K 10.51% 2
2014
Q1
$41.3M Buy
420,456
+3,243
+0.8% +$301K 10.22% 2
2013
Q4
$38.2M Sell
417,213
-10,875
-3% -$1M 7.9% 3
2013
Q3
$37.1M Sell
428,088
-4,010
-0.9% -$360K 10.03% 2
2013
Q2
$37.1M Buy
+432,098
New +$36.7M 10.06% 2

Other funds holding JNJ

Henry H. Armstrong Associates's JNJ Position: Q2 2026 in Review

Henry H. Armstrong Associates increased its Johnson & Johnson (JNJ) stake by 0.86% in Q2 2026, buying an estimated $643K and bringing the position to 322,853 shares worth $82M. The position accounts for 7.94% of the portfolio, ranked #4.

Henry H. Armstrong Associates first reported a position in JNJ in Q2 2013 and has held it in 53 quarters since. 2,379 funds tracked by Wall St. Rank hold JNJ as of Q2 2026.

  • Henry H. Armstrong Associates held 322,853 shares of Johnson & Johnson worth $82M as of Q2 2026.
  • Henry H. Armstrong Associates bought 2,757 Johnson & Johnson shares in Q2 2026, an estimated $643K.
  • Johnson & Johnson made up 7.94% of Henry H. Armstrong Associates's portfolio in Q2 2026, its #4 holding.
  • Henry H. Armstrong Associates first reported a position in Johnson & Johnson in Q2 2013 and has held it in 53 quarters since.
  • 2,379 funds tracked by Wall St. Rank held Johnson & Johnson as of Q2 2026.

Based on Henry H. Armstrong Associates's 13F filing for Q2 2026, filed 7 Jul 2026.